Prospects to improve chimeric antigen receptor T-cell therapy for solid tumors

Immunotherapy

Volumn 8, Issue 12, 2016, Pages 1355-1361

  Jin, Chuan ^a   Yu, Di ^a   Essand, Magnus ^a  

^a UPPSALA UNIVERSITY   (Sweden)

Author keywords

bystander immunity; CAR T cells; immune suppression

Indexed keywords

CATALASE; CD19 ANTIGEN; CD28 ANTIGEN; CHIMERIC ANTIGEN RECEPTOR; GANGLIOSIDE GD2; INTERLEUKIN 12; INTERLEUKIN 14; INTERLEUKIN 7; PROGRAMMED DEATH 1 RECEPTOR; SEPRASE; CANCER VACCINE; HYBRID PROTEIN; LYMPHOCYTE ANTIGEN RECEPTOR;

ADOPTIVE TRANSFER; ANTIGEN PRESENTING CELL; B CELL LYMPHOMA; BYSTANDER EFFECT; CANCER ASSOCIATED FIBROBLAST; CELL ENGINEERING; CELL EXPANSION; CELL THERAPY; CHEMOSENSITIVITY; CLINICAL TRIAL (TOPIC); CYTOKINE PRODUCTION; ENZYME RELEASE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; NONHUMAN; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; PROTEIN TARGETING; REVIEW; SOLID TUMOR; STROMA; T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR MICROENVIRONMENT; ADOPTIVE IMMUNOTHERAPY; ANIMAL; B LYMPHOCYTE; GENETICS; IMMUNOLOGY; METABOLISM; NEOPLASMS; PHYSIOLOGY; PROCEDURES; TRANSPLANTATION; TRENDS; TUMOR ESCAPE;

ANIMALS; ANTIGENS, CD19; B-LYMPHOCYTES; CANCER VACCINES; HUMANS; IMMUNOTHERAPY, ADOPTIVE; NEOPLASMS; RECEPTORS, ANTIGEN, T-CELL; RECOMBINANT FUSION PROTEINS; T-LYMPHOCYTES; TUMOR ESCAPE; TUMOR MICROENVIRONMENT;

EID: 85007277396     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt-2016-0125     Document Type: Review

References (66)

1. Davila ML, Riviere I, Wang X et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci. Transl. Med. 6(224), 224ra225 (2014).
2. Maude SL, Frey N, Shaw PA et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N. Engl. J. Med. 371(16), 1507-1517 (2014).
3. Zhang W-Y, Wang Y, Guo Y-L et al. Treatment of CD20-directed Chimeric Antigen Receptor-modified T cells in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an early Phase IIa trial report. Signal Transduction And Targeted Therapy 1, 16002 (2016).
4. Porter DL, Hwang WT, Frey NV et al. Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. Sci. Transl. Med. 7(303), 303ra139 (2015).
5. Kochenderfer JN, Dudley ME, Feldman SA et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood 119(12), 2709-2720 (2012).
6. Louis CU, Savoldo B, Dotti G et al. Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma. Blood 118(23), 6050-6056 (2011).
7. Kakarla S, Gottschalk S. CAR T cells for solid tumors: armed and ready to go? Cancer J. 20(2), 151-155 (2014).
8. Klebanoff CA, Rosenberg SA, Restifo NP. Prospects for gene-engineered T cell immunotherapy for solid cancers. Nat. Med. 22(1), 26-36 (2016).
9. Eil R, Vodnala SK, Clever D et al. Ionic immune suppression within the tumour microenvironment limits T cell effector function. Nature 537(7621), 539-543 (2016).
10. Walunas TL, Lenschow DJ, Bakker CY et al. CTLA-4 can function as a negative regulator of T cell activation. Immunity 1(5), 405-413 (1994).
11. Freeman GJ, Long AJ, Iwai Y et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J. Exp. Med. 192(7), 1027-1034 (2000).
12. Turley SJ, Cremasco V, Astarita JL. Immunological hallmarks of stromal cells in the tumour microenvironment. Nat. Rev. Immunol. 15(11), 669-682 (2015).
13. Kalluri R, Zeisberg M. Fibroblasts in cancer. Nat. Rev. Cancer 6(5), 392-401 (2006).
14. Schuberth PC, Hagedorn C, Jensen SM et al. Treatment of malignant pleural mesothelioma by fibroblast activation protein-specific re-directed T cells. J. Transl. Med. 11, 187 (2013).
15. Ferrara N, Alitalo K. Clinical applications of angiogenic growth factors and their inhibitors. Nat. Med. 5(12), 1359-1364 (1999).
16. Chinnasamy D, Yu Z, Theoret MR et al. Gene therapy using genetically modified lymphocytes targeting VEGFR-2 inhibits the growth of vascularized syngenic tumors in mice. J. Clin. Invest. 120(11), 3953-3968 (2010).
17. Toyokuni S, Okamoto K, Yodoi J, Hiai H. Persistent oxidative stress in cancer. FEBS Lett. 358(1), 1-3 (1995).
18. Ligtenberg MA, Mougiakakos D, Mukhopadhyay M et al. Coexpressed catalase protects chimeric antigen receptorredirected T cells as well as bystander cells from oxidative stress-induced loss of antitumor activity. J. Immunol. 196(2), 759-766 (2016).
19. Liu K, Rosenberg SA. Transduction of an IL-2 gene into human melanoma-reactive lymphocytes results in their continued growth in the absence of exogenous IL-2 and maintenance of specific antitumor activity. J. Immunol. 167(11), 6356-6365 (2001).
20. Liu K, Rosenberg SA. Interleukin-2-independent proliferation of human melanoma-reactive T lymphocytes transduced with an exogenous IL-2 gene is stimulation dependent. J. Immunother. 26(3), 190-201 (2003).
21. Heemskerk B, Liu K, Dudley ME et al. Adoptive cell therapy for patients with melanoma, using tumor-infiltrating lymphocytes genetically engineered to secrete interleukin-2. Hum. Gene Ther. 19(5), 496-510 (2008).
22. Hsu C, Hughes MS, Zheng Z, Bray RB, Rosenberg SA, Morgan RA. Primary human T lymphocytes engineered with a codon-optimized IL-15 gene resist cytokine withdrawalinduced apoptosis and persist long-term in the absence of exogenous cytokine. J. Immunol. 175(11), 7226-7234 (2005).
23. Hsu C, Jones SA, Cohen CJ et al. Cytokine-independent growth and clonal expansion of a primary human CD8+ T-cell clone following retroviral transduction with the IL-15 gene. Blood 109(12), 5168-5177 (2007).
24. Hoyos V, Savoldo B, Quintarelli C et al. Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety. Leukemia 24(6), 1160-1170 (2010).
25. Zhang L, Kerkar SP, Yu Z et al. Improving adoptive T cell therapy by targeting and controlling IL-12 expression to the tumor environment. Mol. Ther. 19(4), 751-759 (2011).
26. Kerkar SP, Goldszmid RS, Muranski P et al. IL-12 triggers a programmatic change in dysfunctional myeloid-derived cells within mouse tumors. J. Clin. Invest. 121(12), 4746-4757 (2011).
27. Kerkar SP, Leonardi AJ, Van Panhuys N et al. Collapse of the tumor stroma is triggered by IL-12 induction of Fas. Mol. Ther. 21(7), 1369-1377 (2013).
28. Pegram HJ, Lee JC, Hayman EG et al. Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning. Blood 119(18), 4133-4141 (2012).
29. Chmielewski M, Abken H. TRUCKs: the fourth generation of CARs. Expert Opin. Biol. Ther. 15(8), 1145-1154 (2015).
30. Morsut L, Roybal KT, Xiong X et al. Engineering customized cell sensing and response behaviors using synthetic Notch receptors. Cell 164(4), 780-791 (2016).
31. Roybal KT, Williams JZ, Morsut L et al. Engineering T cells with customized therapeutic response programs using synthetic Notch receptors. Cell 167(2), 419-432 e416 (2016).
32. Klebanoff CA, Restifo NP. Customizing functionality and payload delivery for receptor-engineered T cells. Cell 167(2), 304-306 (2016).
33. Motz GT, Santoro SP, Wang LP et al. Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors. Nat. Med. 20(6), 607-615 (2014).
34. Di Stasi A, De Angelis B, Rooney CM et al. T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model. Blood 113(25), 6392-6402 (2009).
35. Craddock JA, Lu A, Bear A et al. Enhanced tumor trafficking of GD2 chimeric antigen receptor T cells by expression of the chemokine receptor CCR2b. J. Immunother. 33(8), 780-788 (2010).
36. Vera JF, Hoyos V, Savoldo B et al. Genetic manipulation of tumor-specific cytotoxic T lymphocytes to restore responsiveness to IL-7. Mol. Ther. 17(5), 880-888 (2009).
37. Foster AE, Dotti G, Lu A et al. Antitumor activity of EBVspecific T lymphocytes transduced with a dominant negative TGF-beta receptor. J. Immunother. 31(5), 500-505 (2008).
38. Bollard CM, Rossig C, Calonge MJ et al. Adapting a transforming growth factor beta-related tumor protection strategy to enhance antitumor immunity. Blood 99(9), 3179-3187 (2002).
39. Stephan MT, Ponomarev V, Brentjens RJ et al. T cell-encoded CD80 and 4-1BBL induce auto-and transcostimulation, resulting in potent tumor rejection. Nat. Med. 13(12), 1440-1449 (2007).
40. Liu X, Ranganathan R, Jiang S et al. A chimeric switchreceptor targeting PD1 augments the efficacy of secondgeneration CAR T cells in advanced solid tumors. Cancer Res. 76(6), 1578-1590 (2016).
41. Leen AM, Sukumaran S, Watanabe N et al. Reversal of tumor immune inhibition using a chimeric cytokine receptor. Mol. Ther. 22(6), 1211-1220 (2014).
42. Lizotte PH, Ivanova EV, Awad MM et al. Multiparametric profiling of non-small-cell lung cancers reveals distinct immunophenotypes. JCI Insight 1(14), e89014 (2016).
43. Becht E, Giraldo NA, Germain C et al. Immune contexture, immunoscore, and malignant cell molecular subgroups for prognostic and theranostic classifications of cancers. Adv. Immunol. 130, 95-190 (2016).
44. Rizvi NA, Hellmann MD, Snyder A et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348(6230), 124-128 (2015).
45. Robert C, Schachter J, Long GV et al. Pembrolizumab versus ipilimumab in advanced melanoma. N. Engl. J. Med. 372(26), 2521-2532 (2015).
46. Choudhury N, Nakamura Y. Importance of immunopharmacogenomics in cancer treatment: patient selection and monitoring for immune checkpoint antibodies. Cancer Sci. 107(2), 107-115 (2016).
47. Sun Z, Fourcade J, Pagliano O et al. IL10 and PD-1 cooperate to limit the activity of tumor-specific CD8+ T cells. Cancer Res. 75(8), 1635-1644 (2015).
48. Raskovalova T, Lokshin A, Huang X et al. Inhibition of cytokine production and cytotoxic activity of human antimelanoma specific CD8+ and CD4+ T lymphocytes by adenosine-protein kinase A type I signaling. Cancer Res. 67(12), 5949-5956 (2007).
49. Mittal D, Young A, Stannard K et al. Antimetastatic effects of blocking PD-1 and the adenosine A2A receptor. Cancer Res. 74(14), 3652-3658 (2014).
50. Munn DH, Mellor AL. Indoleamine 2,3-dioxygenase and tumor-induced tolerance. J. Clin. Invest. 117(5), 1147-1154 (2007).
51. Holmgaard RB, Zamarin D, Munn DH, Wolchok JD, Allison JP. Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4. J. Exp. Med. 210(7), 1389-1402 (2013).
52. Spranger S, Koblish HK, Horton B, Scherle PA, Newton R, Gajewski TF. Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8(+) T cells directly within the tumor microenvironment. J Immunother. Cancer 2, 3 (2014).
53. Ninomiya S, Narala N, Huye L et al. Tumor indoleamine 2,3-dioxygenase (IDO) inhibits CD19-CAR T cells and is downregulated by lymphodepleting drugs. Blood 125(25), 3905-3916 (2015).
54. Levine BL, Bernstein WB, Connors M et al. Effects of CD28 costimulation on long-term proliferation of CD4+ T cells in the absence of exogenous feeder cells. J. Immunol. 159(12), 5921-5930 (1997).
55. Maus MV, Thomas AK, Leonard DG et al. Ex vivo expansion of polyclonal and antigen-specific cytotoxic T lymphocytes by artificial APCs expressing ligands for the T-cell receptor, CD28 and 4-1BB. Nat. Biotechnol. 20(2), 143-148 (2002).
56. Rushworth D, Jena B, Olivares S et al. Universal artificial antigen presenting cells to selectively propagate T cells expressing chimeric antigen receptor independent of specificity. J. Immunother. 37(4), 204-213 (2014).
57. Singh H, Figliola MJ, Dawson MJ et al. Reprogramming CD19-specific T cells with IL-21 signaling can improve adoptive immunotherapy of B-lineage malignancies. Cancer Res. 71(10), 3516-3527 (2011).
58. Dudley ME, Wunderlich J, Nishimura MI et al. Adoptive transfer of cloned melanoma-reactive T lymphocytes for the treatment of patients with metastatic melanoma. J. Immunother. 24(4), 363-373 (2001).
59. Van De Griend RJ, Van Krimpen BA, Bol SJ, Thompson A, Bolhuis RL. Rapid expansion of human cytotoxic T cell clones: growth promotion by a heat-labile serum component and by various types of feeder cells. J. Immunol. Methods 66(2), 285-298 (1984).
60. Gattinoni L, Klebanoff CA, Palmer DC et al. Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells. J. Clin. Invest. 115(6), 1616-1626 (2005).
61. Cieri N, Camisa B, Cocchiarella F et al. IL-7 and IL-15 instruct the generation of human memory stem T cells from naive precursors. Blood 121(4), 573-584 (2013).
62. Jin C, Yu D, Hillerdal V, Wallgren A, Karlsson-Parra A, Essand M. Allogeneic lymphocyte-licensed DCs expand T cells with improved antitumor activity and resistance to oxidative stress and immunosuppressive factors. Molecular Therapy. Methods & Clinical Development 1, 14001 (2014).
63. Riddell SR, Sommermeyer D, Berger C et al. Adoptive therapy with chimeric antigen receptor-modified T cells of defined subset composition. Cancer J. 20(2), 141-144 (2014).
64. Wang X, Naranjo A, Brown CE et al. Phenotypic and functional attributes of lentivirus-modified CD19-specific human CD8+ central memory T cells manufactured at clinical scale. J. Immunother. 35(9), 689-701 (2012).
65. Gattinoni L, Lugli E, Ji Y et al. A human memory T cell subset with stem cell-like properties. Nat. Med. 17(10), 1290-1297 (2011).
66. Turtle CJ, Hanafi LA, Berger C et al. Immunotherapy of non-Hodgkin's lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells. Sci. Transl. Med. 8(355), 355ra116 (2016).